• Corpus ID: 29611540

articleNSC 109268 potentiates cisplatin-induced cell death in a p 53-independent manner

  title={articleNSC 109268 potentiates cisplatin-induced cell death in a p 53-independent manner},
  author={Eswar Shankar and Chandreyi Basu and Brett Adkins and Wolfram Siede and Alakananda Basu},
Background: Ovarian cancer is the leading cause of death among gynecological cancers. Cisplatin is one of the most effective anticancer drugs used in the treatment of ovarian cancer. Development of resistance to cisplatin limits its therapeutic use. Most of the anticancer drugs, including cisplatin, are believed to kill cancer cells by inducing apoptosis and a defect in apoptotic signaling can contribute to drug resistance. The tumor suppressor protein p53 plays a critical role in DNA damage… 
1 Citations

Figures from this paper


p53 gene status and chemosensitivity in ovarian cancer.
P53 gene status contributes the sensitivity to CDDP in ovarian cancer, and combination treatment of p53 gene transduction and CDDP may be an effective therapeutic modality for ovarian cancer without wild-type p53 genes.
Prolonged wild-type p53 protein accumulation and cisplatin resistance.
It is demonstrated that in A2780 and CP70 cells resistance to cisplatin correlates with prolonged p53 protein stabilization and accumulation, and there was no difference in p21WAF-1 half-life between the two cell lines.
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression
The known activities of NSC109268 as proteasome or phosphatase inhibitor could explain the phenotype of S-phase delay by assuming a higher initial DNA damage load, inhibition of DNA translesion synthesis or extended checkpoint arrest.
Cell death pathways in response to antitumor therapy.
It is critically reviewed here how antitumor therapy may elicit the response of human cancers through different cell pathways leading to cell death.
Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
The results suggest that the loss of functional p53 can increase cisplatin cytotoxicity in A2780, with loss of G(1)/S checkpoint control and decreased cis platin-DNA adduct repair, but these effects can be circumvented by the use of JM335, which forms different DNA-platinum adducts.
Cisplatin: mode of cytotoxic action and molecular basis of resistance
The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
A significant correlation has been found between p53 accumulation, type of mutation, and pathological response to cisplatin-based therapy in ovarian cancer patients, consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.
Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance.
The results suggest that PKCepsilon acts upstream of mitochondria and mediates TRAIL resistance via both Bcl-2 and Bid in MCF-7 cells.
Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells
The experiments identify p53 as the main pathway producing a large-scale transcriptional response after cisplatin treatment in these cells containing wild-type p53, and knockdown of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells.
Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells
DDP down-regulated the amount of its major influx transporter in cultured human ovarian carcinoma cells in a concentration- and time-dependent manner and it occurred very quickly relative to the half-life of the drug.